CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
51.59
-0.39 (-0.76%)
Feb 5, 2026, 9:45 AM EST - Market open
CG Oncology Revenue
CG Oncology had revenue of $1.67M in the quarter ending September 30, 2025, with 3,774.42% growth. This brings the company's revenue in the last twelve months to $2.17M, up 217.84% year-over-year. In the year 2024, CG Oncology had annual revenue of $1.14M with 458.33% growth.
Revenue (ttm)
$2.17M
Revenue Growth
+217.84%
P/S Ratio
1,928.72
Revenue / Employee
$19,239
Employees
113
Market Cap
4.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.14M | 935.00K | 458.33% |
| Dec 31, 2023 | 204.00K | 13.00K | 6.81% |
| Dec 31, 2022 | 191.00K | -10.17M | -98.16% |
| Dec 31, 2021 | 10.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCGON News
- 20 days ago - CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 25 days ago - CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene - Seeking Alpha
- 27 days ago - CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC - GlobeNewsWire
- 4 weeks ago - CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - CG Oncology Undervalued Going Into A Busy 2026 - Seeking Alpha
- 2 months ago - New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 2 months ago - CG Oncology Announces New Board Member and Board Transition - GlobeNewsWire
- 2 months ago - CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire